Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01131676 · ClinicalTrials.gov registry record · Phase 3
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,064
- Enrollment target
NCT01131676 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,064 participants.
The verdict
NCT01131676, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,064 participants
- Enrollment target
Study Summary
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
Interventions
- DRUG BI 10773 low dose
- DRUG BI 10773 high dose
- DRUG Placebo BI 10773 high dose
- DRUG Placebo BI 10773 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,064 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01131676
The ClinicalTrials.gov registry entry for NCT01131676 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,064 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BI 10773 low dose is the first listed.
NCT01131676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01131676 about?
NCT01131676 is a clinical study titled "BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).". The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
What is the current status of trial NCT01131676?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,064 participants. The study started on 2010-07. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01131676?
The interventions under investigation include: BI 10773 low dose (DRUG), BI 10773 high dose (DRUG), Placebo BI 10773 high dose (DRUG), Placebo BI 10773 low dose (DRUG).
Who is sponsoring clinical trial NCT01131676?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.